Volume 3, Issue 4 (November 2024)
Health Science Monitor 2024, 3(4): 306-323 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rezaei E, Aliasgarzadeh S, Mikaeili mirak S, Tayyar-Iravanlou F. Factors influencing COVID-19 vaccine breakthrough infections: an analysis of healthcare workers in Ardabil, Iran. Health Science Monitor 2024; 3 (4) :306-323
URL: http://hsm.umsu.ac.ir/article-1-186-en.html
URL: http://hsm.umsu.ac.ir/article-1-186-en.html
Students Research Committee, School of Paramedical Sciences, Ardabil University of Medical Sciences, Ardabil, Iran
Abstract: (15 Views)
Background & Aims: Investigating re-infection with COVID-19 is necessary due to the existence of genetic differences among populations after a general vaccination plan. In addition to genetic differences, gender, age, the presence of underlying diseases, and the type of vaccine are factors that affect the rate and severity of re-infection after vaccination.
Materials & Methods: Demography, physical activity and nutrition, underlying diseases, the period of involvement with the COVID-19 pandemic, and the percentage of re-infection before and after each stage of vaccination of the medical staff at Imam Khomeini Hospital in Ardabil (Iran) were evaluated. Our study was performed in a descriptive-analytical manner among 149 healthcare workers. The data were collected using a valid and reliable questionnaire and analyzed using SPSS version 26.
Results: According to the results, 69.1% of healthcare workers had a positive PCR test or symptoms of COVID-19 before the first injection of the vaccine. The types of injected vaccines included AstraZeneca, Sinopharm, Sputnik V, Bharat, Barekat, Spicogen, and PastoCovac. After the injection of the first dose of the vaccine, the number of severe cases decreased from 30.9% to 10.7%, which indicates the effectiveness of the vaccination.
Conclusion: The lowest rate of re-infection was observed in people with good physical activity compared to those who were less active (9.6% versus 59.6%). The highest rate of re-infection with COVID-19 between the first and second doses of the vaccine was related to Sinopharm, Sputnik V, and AstraZeneca. The highest rate of re-infection (82.7%) was in the age group under 40 years old.
Materials & Methods: Demography, physical activity and nutrition, underlying diseases, the period of involvement with the COVID-19 pandemic, and the percentage of re-infection before and after each stage of vaccination of the medical staff at Imam Khomeini Hospital in Ardabil (Iran) were evaluated. Our study was performed in a descriptive-analytical manner among 149 healthcare workers. The data were collected using a valid and reliable questionnaire and analyzed using SPSS version 26.
Results: According to the results, 69.1% of healthcare workers had a positive PCR test or symptoms of COVID-19 before the first injection of the vaccine. The types of injected vaccines included AstraZeneca, Sinopharm, Sputnik V, Bharat, Barekat, Spicogen, and PastoCovac. After the injection of the first dose of the vaccine, the number of severe cases decreased from 30.9% to 10.7%, which indicates the effectiveness of the vaccination.
Conclusion: The lowest rate of re-infection was observed in people with good physical activity compared to those who were less active (9.6% versus 59.6%). The highest rate of re-infection with COVID-19 between the first and second doses of the vaccine was related to Sinopharm, Sputnik V, and AstraZeneca. The highest rate of re-infection (82.7%) was in the age group under 40 years old.
Type of Study: Research |
Subject:
Health Protection including control of communicable and non-communicable diseases
Received: 2024/07/2 | Accepted: 2024/09/17 | Published: 2024/11/20
Received: 2024/07/2 | Accepted: 2024/09/17 | Published: 2024/11/20
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
